Expanding the phenotypic spectrum of MBOAT7‐related intellectual disability by Jacher, Joseph E. et al.
R E S E A R CH A R T I C L E
Expanding the phenotypic spectrum of MBOAT7-related
intellectual disability
Joseph E. Jacher1 | Nikita Roy2 | Mohammad Ghaziuddin2 | Jeffrey W. Innis1,3,4
1Department of Pediatrics and Communicable
Diseases, Division of Pediatric Genetics,
Metabolism and Genomic Medicine, University
of Michigan, Ann Arbor, Michigan
2Psychiatry, University of Michigan, Ann
Arbor, Michigan
3Human Genetics, University of Michigan, Ann
Arbor, Michigan
4Internal Medicine, University of Michigan,
Ann Arbor, Michigan
Correspondence
Jeffrey W. Innis, MD, PhD, D5240 Medical
Professional Building, 1500 E Medical Center
Drive, Ann Arbor, MI 48109.
Email: innis@med.umich.edu
Abstract
MBOAT7 gene pathogenic variants are a newly discovered and rare cause for intellectual
disability, autism spectrum disorder (ASD), seizures, truncal hypotonia, appendicular
hypertonia, and below average head sizes (ranging from −1 to −3 standard deviations).
There have been only 16 individuals previously reported who have MBOAT7-related
intellectual disability, all of whom were younger than 10 years old and from consanguin-
eous relationships. Thus, there is a lack of phenotypic information for adolescent and
adult individuals with this disorder. Medical genetics and psychiatric evaluations in a 14-
year-old female patient with a history of global developmental delay, intellectual disabil-
ity, overgrowth with macrocephaly, metrorrhagia, seizures, basal ganglia hyperintensities,
nystagmus, strabismus with amblyopia, ASD, anxiety, attention deficit hyperactivity dis-
order (ADHD), aggressive outbursts, and hyperphagia included a karyotype, methylation
polymerase chain reaction for Prader-Willi/Angelman syndrome, chromosome microar-
ray, and whole exome sequencing (WES), ADOS2, and ADI-R. WES identified a homozy-
gous, likely pathogenic variant in the MBOAT7 gene (c.855-2A>G). This is the oldest
known patient with MBOAT7-related intellectual disability, whose unique features com-
pared with previously described individuals include overgrowth with macrocephaly,
metrorrhagia, ophthalmological abnormalities, basal ganglia hyperintensities, unspecified
anxiety disorder, and ADHD; combined type; and hyperphagia with the absence of appen-
dicular hypertonia and cortical atrophy. More individuals need to be identified in order to
delineate the full clinical spectrum of this disorder.
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1 | INTRODUCTION
1.1 | Background
Genetic testing for neurodevelopmental disorders has been rapidly
increasing over the last decade. New genetic disorders are being dis-
covered at a rate not seen before, especially with the use of whole
exome sequencing (WES) (The Deciphering Developmental Disorders
Study, 2017). WES has become the new gold standard test for
patients with undiagnosed genetic disorders with a diagnostic yield,
after an initial workup, of around 36% (Clark et al., 2018). Johansen
et al. (2016) were the first group to discuss pathogenic variants in
MBOAT7 (OMIM 606048) as a rare cause for human neu-
rodevelopmental delays, autism spectrum disorder (ASD), and seizures
in a total of 16 individuals. ASD is a well-described developmental dis-
order with both social and communication deficits in addition to ste-
reotyped, ritualistic, and/or repetitive behaviors (Nazeer &
Ghaziuddin, 2012). Children who have intellectual disability, with or
without MBOAT7 pathogenic variants, are known to have higher
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overall rates of various psychopathologies (Dykens, 2000), which
can include disruptive disorders, mood disorders, and/or anxiety dis-
orders (Emerson, 2003). In this article, we report a 14-year-old
female with MBOAT7-related intellectual disability who has a history
of global developmental delay, intellectual disability, overgrowth
with macrocephaly, metrorrhagia, seizures, basal ganglia hyper-
intensities, nystagmus, strabismus with amblyopia, ASD, attention
deficit hyperactivity disorder (ADHD), anxiety, irritable mood, per-
severative behaviors, aggressive outbursts, and hyperphagia.
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
Informed consent under the University of Michigan IRB protocol
HUM00065360 was obtained from the family for this article in com-
pliance with institutional and national ethics regulations.
2.2 | Chromosome analysis
Chromosome analysis was performed on 20 metaphase cells from
peripheral blood at the 550 band level of resolution using the
G-banding method.
2.3 | Prader-Willi/Angelman syndrome methylation
testing
Southern blot methylation analysis was performed on DNA obtained
from peripheral blood used the SNRPN probe and digestion with Not
I and Xba I.
2.4 | Chromosome microarray analysis
The chromosome microarray was performed using the Illumina
CytoSNP-850 K (GRCh37/hg19 genome assembly) platform on DNA
extracted from peripheral blood.
2.5 | Whole exome sequencing (trio)
WES was performed at Ambry Genetics Corp. Genomic
deoxyribonucleic acid was isolated from whole blood. Proband and
parental samples were prepared using the SeqCap EZ VCRome 2.0
(Roche NimbleGen) or the IDT xGen Exome Research Panel V1.0. Final
quantified libraries were seeded onto an Illumina flow cell and
sequenced using paired-end, 100 or 150 cycle chemistry on the Illumina
HiSeq or NextSeq. Variants were confirmed by Sanger sequencing.
3 | RESULTS
3.1 | Medical genetics evaluation
The female patient was born without a history of in utero teratogenic
exposure, but the pregnancy was complicated by vaginal bleeding at
2 months' gestation as well as decreased fetal movements beginning
at 6 months' gestation. She was born via complicated delivery (ardu-
ous labor and faint fetal heart tones) to a 23 year old, G1P1 mother at
38–4/7 weeks' gestation. Apgar scores were 8 and 9 at 1 and 5 min,
respectively. There was no reported consanguinity, though the
parents are from the same village in Lebanon. The birth weight was
2,835 g (18th percentile), the birth length was 55 cm (+3 standard
deviations [SD]), and the head circumference was 34 cm (54th
percentile). Our patient had hypotonia throughout infancy that
resolved in childhood. She had four simple partial seizures within a
24-hr period at 17 months of age and was treated with an anti-
epileptic for 7 months before being weaned off with no seizure recur-
rence. Vision assessments at ages 7 months and 3 years have been
remarkable for intermittent esotropia, nystagmus, and unilateral stra-
bismus with amblyopia; she underwent laser surgery for the strabis-
mus at 1 year of age.
The most recent brain magnetic resonance imaging (MRI) was per-
formed at 3.5 years of age and revealed flare signal hyperintensities
within both basal ganglia, which appeared stable compared with the
prior study at age 14 months. The signal abnormalities in the dentate
nuclei bilaterally and retrotrigonal white matter bilaterally appeared
slightly decreased in size and slightly less conspicuous compared with
prior MRI. There were also signal abnormalities in the subcortical
white matter of the left precentral gyrus and the anterior aspect of
the superior frontal gyrus on the left, which was similar to the prior
MRI. There were no new lesions appreciated. Neurological and neuro-
radiological evaluation of her head MRI revealed primarily cerebellar
and basal ganglia involvement, regions known to be more susceptible
to hypoxic–ischemic damage or mitochondrial dysfunction. However,
there is no evidence to suggest our patient ever had any hypoxic–
ischemic event. It is plausible that these MRI findings could be associ-
ated with some of her neurocognitive delays. She had a normal bone
age study at age 10.5 years. Menarche occurred at 13 years of age
and she has had metrorrhagia since then. At first, menses occurred
every 2–3 months, lasting 10 days with approximately 4 days of heavy
bleeding (needing to change pads every 1.5 hr). These symptoms have
been successfully managed with ethinyl estradiol and levonorgestrel.
At age 14.5 years, her head circumference was 58 cm (between +2.5
and + 3 SD), weight was 92 kg (+2.29 SD), and height was 171 cm
(+1.48 SD). The dysmorphology exam at this time was remarkable for
macrocephaly, mild enophthalmos bilaterally, acanthosis nigricans
affecting the neck and flexor creases of elbows, abdominal striae, and
hirsutism of the face, neck, and abdomen. There were no other nota-
ble dysmorphic features (Figure 1).
3.2 | Genetic testing
Chromosome analysis and Prader-Willi/Angelman syndrome methyla-
tion tests were both normal. Chromosome microarray analysis identi-
fied numerous regions of copy neutral absence of single nucleotide
polymorphism heterozygosity. WES identified a homozygous, likely
pathogenic variant in the membrane bound O-acyltransferase domain
containing 7 (MBOAT7) gene (c.855-2A>G). Cosegregation analysis of
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the c.855-2A>G alteration revealed that the proband's unaffected
mother and unaffected father were both heterozygous for the variant.
3.3 | Psychiatric evaluation
The patient was referred to psychiatry at 14 years of age for diag-
nosis and management of her behavioral symptoms including
impulsivity, hyperactivity, defiance, perseverative behaviors, disrup-
tiveness, and hyperphagia. These symptoms were pervasive across
environments and caused distress to the parents and family. Psy-
chological testing demonstrated a verbal and related behavior
capacity in the range of 1–18 months of age. After initial compre-
hensive psychiatric evaluation her presentation was most consistent
with that of ASD, unspecified anxiety disorder, and ADHD. There
was no reported family history of intellectual disability, ASD, or
other psychiatric diagnosis.
Developmental concerns were noted when she was unable to sit
up independently and not crawling at age 9 months. She walked by
age 2.5 years. Parents describe this patient as very rigid in having
strict routines, needing to be repeated in exact ways, from the same
people, in the same tone of voice, and struggling with transitions from
a very young age. Regression in behaviors is often precipitated by
changes in schedule. While parents deny a sustained restricted inter-
est, she does enjoy playing with electronics (phones and computers),
and is easily reinforced by food. She also has sensory avoidance of
certain sounds including, fireworks and the “happy birthday” song.
Social deficits were also noted at a very young age due to trouble with
interpersonal skills. She is slow to warm up and often does not inter-
act with others whom are not her mother, father, grandmother, or
cousin. She is generally avoidant and suspicious of others; she prefers
solitary play or with just her parents. Her eye contact is generally
intermittent, rarely sustained, and often avoidant. Social reciprocity is
lacking; she often will not follow commands and becomes
perseverative on particular topics of interest to her. Along with delay
in motor milestones, speech delays were noted around age 1.5 years
when she was essentially nonverbal. At the age of 14 years, her
vocabulary consists mostly of one to two word phrases, for example,
“I done” or “mama.” She expresses about 10 words in English. She
does understand both English and Arabic with her receptive language
being much more developed than expressive language. Finally, disrup-
tive behaviors have been consistent, since she was young. These
include yelling, spitting, shoving, hitting, crying, oppositionality, sense-
less refusal of requests, and throwing items. Such behaviors can be
noted in the setting of limits, but also at times are unprovoked. She
often becomes dysregulated if requests are not met immediately. She
was evaluated through Michigan's Community Mental Health using
the ADOS2 and ADI-R, both of which confirmed the diagnosis
of ASD.
Comorbid with ASD was prominent symptoms of anxiety. She is
wary of all new faces, very slow to warm up, easily tearful, and gener-
ally avoidant of new places and people. The family often has to allow
for extra time for her to accustom herself to a new situation before
she will enter. She often will stand outside the door of a doctor's
office or require 10–25 min to get out of the car in a new environ-
ment. If not for her parents' insistence, her preference would be to
stay in the home. She has a lot of trouble with meeting new people,
and often will not go places where the door has to be shut. She cur-
rently sleeps well with pharmacological interventions; however, prior
to initiation of medication, sleep was fragmented with 20+ awaken-
ings per night. She uses Clonidine 0.1 mg at bedtime with good effect.
The multidimensional anxiety scale for children was completed, which
supported the diagnosis of unspecified anxiety disorder, with scores
well in the clinically significant range.
Upon evaluation, ADHD was suspected due to descriptions of
hyperactivity, inattention, and distractibility. Vanderbilt rating scale
was significant for primarily inattention issues, however, on multiple
mental status exams, it was noted that she could be intrusive, distract-
ible, and hyperactive. Parents described her as active all day with diffi-
culty sitting down to watch television, or playing with just one
activity. She has a tendency to switch activities within a few minutes
and requires frequent redirection. She paces around at home and it
takes a significant amount of time to settle her to bed.
Food appeared to be a major reinforcer of behaviors. Her parents
reported that she always thinks about food and generally overeats.
She is above the 99th percentile for weight. Her parents keep locks
on the refrigerator and cupboard doors. If not, she will forage as much
food as she can until she is interrupted. Her parents describe a lack of
understanding of satiety and she needs frequent redirection away
from food. She often eats five to six times per day and would eat
more if she were provided with the opportunity. Her symptoms cause
much distress within the home. While many antipsychotics can
increase appetite, this individual was never on a medication that
would have this effect until August 2019. Her hyperphagia has
remained unchanged despite the addition of Abilify 2 mg at bedtime.
While on Abilify, she has had no worsening behaviors.
F IGURE 1 Frontal profile facial view of the proband at 14 years
11 months of age [Color figure can be viewed at
wileyonlinelibrary.com]
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4 | DISCUSSION
In this report, we describe a female with a novel homozygous, likely
pathogenic variant in the MBOAT7 gene (c.855-2A>G) identified by
WES who has a history of global developmental delay, intellectual dis-
ability, overgrowth with macrocephaly, metrorrhagia, seizures, basal
ganglia hyperintensities, nystagmus, strabismus with amblyopia, ASD,
ADHD, anxiety, irritable mood, aggressive outbursts, and hyperphagia.
She does not have a history of appendicular hypertonia nor cortical
atrophy as described in previous patients (Johansen et al., 2016). The
c.855-2A>G variant is not present in ExAC, ClinVar, 1,000 Genomes
Project, or the Genome Aggregation Database (accessed July 2018).
Variants within the canonical splice acceptor site are typically consid-
ered pathogenic (Richards et al., 2015). The nucleotide position
affected in our patient is well conserved in the MBOAT7 homologs of
available sequenced vertebrate species. In silico models (BDGP &
ESEfinder) predict this alteration to abolish the native splice acceptor
site; however, functional evidence for this variant is unavailable. Stud-
ies have shown that LPIAT1, the protein encoded from MBOAT7, is
essential for cortical lamination, which is necessary for normal neuro-
nal development (Lee et al., 2012). MBOAT7 knockout mice have
abnormal cortical lamination and delayed neuronal migration with
atrophy of the cerebral cortex and hippocampus. These mice were
also typically smaller than their littermates, had unsteady gaits, dys-
morphic features, difficulty feeding, and early death (Anderson et al.,
2013; Lee et al., 2012). Work with this mutant and other models will
be helpful in identifying the genetic pathways affected in LPIAT1
deficiency.
Many of our patient's symptoms are consistent with others with
MBOAT7-related intellectual disability first described in humans by
Johansen et al. (2016). That report described 16 individuals, all born
from consanguineous parents, who all have homozygous pathogenic
variants in the MBOAT7 gene confirming their diagnosis of MBOAT7-
related intellectual disability. The most common symptoms observed
in these individuals include: intellectual disability (16/16) with many
being non-verbal with delayed motor milestones (walking typically
achieved between 2–7 years) (9/16), seizures (10/16), truncal hypoto-
nia in infancy (16/16), appendicular hypertonia (16/16), ASD (7/16),
and, less commonly, brain MRI findings, such as cortical atrophy and
polymicrogyria (2/16). Characterization of the psychiatric aspects of
MBOAT7-related intellectual disability, other than ASD, have not been
presented.
Psychiatric diagnoses are especially prevalent in individuals with
intellectual disability (Dykens, 2000). As with our patient, a full psychi-
atric assessment would be beneficial to those who have
MBOAT7-related intellectual disability. An ASD evaluation may pro-
vide both diagnostic clarification and treatment goals, which may help
to alleviate symptoms and improve overall quality of life for both
patients and families. Confirming other psychiatric diagnoses, includ-
ing ASD, can have implications on school placement, burdens of care,
and the lens through which many children are viewed. Often times,
certain traditional options may not benefit these children, and appro-
priate treatment may begin only after psychiatric diagnoses are
confirmed. We recommend that all patients with MBOAT7-related
intellectual disability have a full psychiatric evaluation to rule in or out
ASD and other comorbid psychopathology, as psychiatric interven-
tions may provide alternate therapeutic interventions and improve
symptoms severity.
As the use of whole exome and genome sequencing continues to
rise, it is expected that more individuals with MBOAT7-related intel-
lectual disability will be identified. Our patient's phenotype expands
upon what has been previously reported revealing overgrowth with
macrocephaly, metrorrhagia, ophthalmological abnormalities, basal
ganglia hyperintensities, Unspecified Anxiety Disorder, ADHD, and
hyperphagia without having appendicular hypertonia or cortical atro-
phy as additional characteristics. Additional older patients with this
disorder need to be evaluated and published in order to delineate
the full clinical spectrum of this rare syndrome. As this occurs, it will
contribute to the development of specific medical management
guidelines.
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